IDH2 inhibition increases sensitivity to CFZ in mantle cell lymphoma and Burkitt lymphoma cells. (A) JeKo-1, (B) SP-49, (C) Mino, (D) Granta-519, (E) HS-Sultan, and (F) Raji cells were left UT, treated with DMSO, CFZ, AGI-6780, or a combination of the 2 drugs. JeKo-1 cells were treated at time 0, 48 hours, and 96 hours with both drugs. SP-49 cells were treated at time 0 and 48 hours with both drugs and at 96 hours with AGI-6780. Mino cells were treated with both drugs at time 0 and with AGI-6780 at 48 and 96 hours. Granta-519 cells were treated at time 0 and 48 hours with both drugs and every 48 hours with AGI-6780. HS-Sultan cells were treated at time 0 with both drugs and every 48 hours with AGI-6780. Raji cells were treated at time 0 and 48 hours with both drugs and every 48 hours with AGI-6780. Cell viability was measured by TMRM or annexin V staining-flow cytometry at the indicated time points. Data are the means ± SD of 4 independent experiments (*P < .05; **P <. 01; ***P <. 001). dpt, days posttreatment.